- Home
- ERNA
as 11-15-2024 4:00pm EST
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 56.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 89.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $2.63 | Next Earning Date: | 11-12-2024 |
| Revenue: | $598,000 | Revenue Growth: | 1072.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Eterna Therapeutics Inc. News
ERNA Breaking Stock News: Dive into ERNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
GlobeNewswire
18 days ago
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
TipRanks
a month ago
Eterna, Factor announce license, collaboration agreement
GlobeNewswire
a month ago
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
GlobeNewswire
6 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire
6 months ago
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
GlobeNewswire
6 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire
6 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
Compare ERNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERNA Eterna Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.